ARCHIVES

FDA Hears More Criticism On Cancer Drug Endpoints; Joint Conferences On Criteria Recommended

This article is from The Cancer Letter archive.

Vol. 15 No. 30 | July 28, 1989

Download PDF Visit The Full Archive

Related Articles

House Appropriations Adds $20 Mil. To Bush Request For NCI, Emphasizes Three Cancers

June 28, 1991

Upon, Panel Lean To Anecdotal Laetrile Study

August 12, 1977

NCAB Considers Discrimination Against Patients, Minority Rates, Smokeless Tobacco

April 12, 1985

ODAC Advises Approval Of Tamoxifen For Male Breast Cancer Treatment

November 27, 1992

DCT Board Approves Concept For BRMP Master Agreement

June 26, 1987

TJU Wins NCI Renewal Of Kimmel Center Core Grant; 11 NY Centers Testing Spiral CT.

July 13, 2001